Targeting Bfl-1 via acute CDK9 inhibition overcomes intrinsic BH3-mimetic resistance in lymphomas. Boiko S, Proia T, San Martin M, Gregory GP, et al. Blood 2021;137:2947-2957.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Boiko S, Proia T, San Martin M, Gregory GP, et al. Targeting Bfl-1 via acute CDK9 inhibition overcomes intrinsic BH3-mimetic resistance in lymphomas. Blood 2021;137:2947-2957.
PMID: 33259592